Cresco Labs Inc. (CRLBF)
(Delayed Data from OTC)
$1.91 USD
+0.09 (4.95%)
Updated May 31, 2024 03:59 PM ET
3-Hold of 5 3
B Value A Growth B Momentum A VGM
Brokerage Reports
Cresco Labs Inc. [CRLBF]
Reports for Purchase
Showing records 1 - 20 ( 128 total )
Company: Cresco Labs Inc.
Industry: Medical - Products
Company: Cresco Labs Inc.
Industry: Medical - Products
Company: Cresco Labs Inc.
Industry: Medical - Products
Company: Cresco Labs Inc.
Industry: Medical - Products
Company: Cresco Labs Inc.
Industry: Medical - Products
Another Strong Quarter as Costs Drain from the Business
Provider: Echelon Welath Partners
Analyst: SEMPLE A
Company: Cresco Labs Inc.
Industry: Medical - Products
1Q24 In-Line, Operational Improvements Continue Ahead of OH
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Cresco Labs Inc.
Industry: Medical - Products
Cannabis ReHash: DEA Intends to Move to Schedule 3, Investors Not Pricing It In
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Cresco Labs Inc.
Industry: Medical - Products
Company: Cresco Labs Inc.
Industry: Medical - Products
Company: Cresco Labs Inc.
Industry: Medical - Products
Good End to the Year of The Core; Improvements Ahead in ''24
Provider: Wedbush Securities Inc.
Analyst: PASCARELLI G
Company: Cresco Labs Inc.
Industry: Medical - Products
Company: Cresco Labs Inc.
Industry: Medical - Products
4Q24 Solid, Margin CF Improvement on Efficiency Gains to Continue
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Cresco Labs Inc.
Industry: Medical - Products
Strong Q423 Shows Improved Strategic Focus and Rightsized Cost Structure. Catalysts Approaching. Upgrading to BUY.
Provider: Echelon Welath Partners
Analyst: SEMPLE A
Company: Cresco Labs Inc.
Industry: Medical - Products
Company: Cresco Labs Inc.
Industry: Medical - Products
Weekly ReHash: February Performance and Valuations
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Cresco Labs Inc.
Industry: Medical - Products
Weekly ReHash: U.S. Cannabis 4Q23 Earnings Week I
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Cresco Labs Inc.
Industry: Medical - Products
Weekly ReHash: Capital Remains Tight but Will Flow with Federal Reform Changes
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Cresco Labs Inc.
Industry: Medical - Products
Weekly ReHash: Percolating Cannabis Technicals, Trading Volume, Valuations
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Cresco Labs Inc.
Industry: Medical - Products
Weekly ReHash: Pressure on DEA to Reschedule After HHS Findings
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Cresco Labs Inc.
Industry: Medical - Products
Weekly ReHash: State Led Growth Story to Continue in 2024
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S